Unicycive's CKD drug oxylanthanum carbonate gets a second FDA rejection over third-party manufacturing issues; shares drop ~50% premarket.
June 30, 2026 08:55 AM EDT
PharmaFDA+Manufacturing
Unicycive gets second CRL for kidney drug as manufacturing woes continue
Anna Brown
News Reporter
Unicycive Therapeutics ($UNCY) stock crashes over 46% as FDA rejects kidney disease drug NDA again over third-party manufacturing…
After Unicycive Therapeutics had its drug application for oxylanthanum carbonate (OLC)
Celcuity's Revtorpyk wins FDA approval but won't launch until late Q3, sending shares down 14% as analysts expected a faster…
After submitting its timed-release version of a decades-old ADHD drug to the FDA nearly a year ago, Kansas City's Cingulate has…
The oral drug, pociredir, was being tested to treat sickle-cell disease, an inherited blood disorder that can trigger pain,…
Sobi’s plan to introduce a challenger to Amgen’s blockbuster gout drug Krystexxa has been put on hold by the FDA. | Sobi’s plan…
